The text provides unaudited financial information of AbbVie Inc. for the first quarter of 2022, including details on company revenues, expenses, earnings, comprehensive income, and balance sheets, among others. It covers the basis of presentation and adjustments made in the financial statements, key figures like net earnings, total assets, and total equity. The disclosures extend to derivatives, fair value measures, contingent consideration, debt and credit facilities, equity stock-based compensation, cash dividends, and the stock repurchase program, detailing key balances, losses, gains, and reclassifications during the disclosed period.
The text discusses the financial condition and results of operations of AbbVie Inc., a global biopharmaceutical company, as of March 31, 2022. The company's product portfolio includes treatments for various medical conditions like immunology, oncology, aesthetics, neuroscience, and eye care. Key financial highlights include worldwide net revenues of $13.5 billion, operating earnings of $4.7 billion, and diluted earnings per share of $2.51 for the three months ended March 31, 2022, with growth in immunology, neuroscience, and aesthetics portfolios. The company detailed strategic objectives, recent global events affecting operations, and developments in significant programs across various medical areas like immunology, oncology, aesthetics, neuroscience, and eye care. Additionally, there's a segment on the company's financial performance, details on net revenues by product, gross margin, selling, general, and administrative expenses, research and development expenses, non-operating expenses, income tax expenses, and an overview of the company's financial position, liquidity, capital resources, and credit risk. The text also provides information on critical accounting policies and forward-looking statements.
Refer to AbbVie's Annual Report on Form 10-K for a detailed discussion on the company's market risk, outlined in Item 7A, "Quantitative and Qualitative Disclosures About Market Risk".
The text discusses AbbVie's evaluation of its disclosure controls and procedures and internal control over financial reporting by its CEO and CFO, concluding that they were effective in ensuring timely and accurate disclosure of required information to the SEC and management. It also mentions that there were no material changes in AbbVie's internal controls during the reported quarter. However, it highlights inherent limitations in control systems that may not prevent all errors or fraud due to various factors like resource constraints and possibility of human error or management override. These limitations mean that controls can't guarantee absolute assurance against misstatements or fraud, and their effectiveness may deteriorate over time due to changing conditions or compliance issues.
The text provides a brief mention of where information related to legal proceedings can be found, directing readers to refer to Note 12 in the Condensed Consolidated Financial Statements for such details.
Apologies, but I need the text parts to provide a summary. Let me know when you send them.
The text provided details about unregistered sales of equity securities and the purchase of shares by the issuer during the periods of January 1, 2022, to March 31, 2022. The total number of shares purchased, average prices, and maximum number or approximate dollar value of shares that may yet be purchased under certain programs were listed. It also mentioned that in addition to shares repurchased on the open market, shares were also purchased for the benefit of participants in the AbbVie Employee Stock Purchase Plan in January, February, and March. These purchases did not include shares surrendered to satisfy tax withholding obligations related to stock-based awards.
I am ready to hear the text parts to provide the summary.
I'm here to help summarize the text for you. Please go ahead and provide the text you'd like me to summarize.
The text provides a comprehensive analysis of AbbVie's financial statements, emphasizing topics such as derivative instruments, fair value measurements, contingent consideration liabilities, and equity stock-based compensation. It delves into the company's use of derivatives, gains and losses from these instruments, as well as details on financial instruments, equity securities, and concentrations of risk. Additionally, insights are given into AbbVie's debt, credit facilities, post-employment benefits, and stock-based compensation expenses related to incentive stock programs.

Furthermore, AbbVie's 2022 Form 10-Q filing demonstrates its active involvement in intellectual property litigations to protect patents for drugs like Humira, Imbruvica, and Vraylar. The report highlights the company's global revenue growth in segments such as immunology, neuroscience, and aesthetics, showcasing strong overall financial performance with revenue, earnings, and cash flows. AbbVie's strategic plans encompass revenue diversification, investment in research and development, pipeline expansion, and cost synergies following the Allergan acquisition. It also addresses the impact of global events like the Russia-Ukraine conflict and ongoing COVID-19 challenges. The text underscores AbbVie's research and innovation focus, with numerous compounds in development stages in areas like immunology, oncology, and eye care, including notable programs like Skyrizi and Rinvoq with FDA approvals for various indications.
The text provides details regarding various exhibits attached to a document related to AbbVie Inc. These include forms of agreements such as Performance-Vested Restricted Stock Unit Agreement, Performance Share Award Agreement, Non-Employee Director RSU Agreement, and others. Additionally, certifications by the Chief Executive Officer and Chief Financial Officer are included, along with financial statements and notes. The document also outlines the filing of an Interactive Data File and the signature of Robert A. Michael as the Vice Chairman and Chief Financial Officer of AbbVie Inc.
